(Q42197985)

English

Assessment of bone mineral density in tenofovir-treated patients with chronic hepatitis B: can the fracture risk assessment tool identify those at greatest risk?

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Assessment of bone mineral density in tenofovir-treated patients with chronic hepatitis B: can the fracture risk assessment tool identify those at greatest risk? (English)

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

1 reference

based on heuristic

inferred from title

chronic hepatitis B

1 reference

based on heuristic

inferred from title

author name string

Upkar S Gill

1

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Alexandra Zissimopoulos

2

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Safa Al-Shamma

3

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Katherine Burke

4

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Mark J W McPhail

5

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

David A Barr

6

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Yiannis N Kallis

7

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Richard T C Marley

8

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Paul Kooner

9

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Graham R Foster

10

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Patrick T F Kennedy

11

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

language of work or name

0 references

publication date

25 August 2014

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Journal of Infectious Diseases

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

211

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

374-382

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

EASL clinical practice guidelines: Management of chronic hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU471

21 January 2018

Hepatology: a home for hepatocellular cancer publications

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU471

21 January 2018

Chronic hepatitis B: a treatment update

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU471

21 January 2018

Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU471

21 January 2018

The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years.

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU471

21 January 2018

Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU471

21 January 2018

Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU471

21 January 2018

Adenosine induces loss of actin stress fibers and inhibits contraction in hepatic stellate cells via Rho inhibition

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU471

21 January 2018

Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU471

21 January 2018

Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU471

21 January 2018

Bone pain due to fractures revealing osteomalacia related to tenofovir-induced proximal renal tubular dysfunction in a human immunodeficiency virus-infected patient

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU471

21 January 2018

The development of hypophosphataemic osteomalacia with myopathy in two patients with HIV infection receiving tenofovir therapy

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU471

21 January 2018

Tenofovir-associated renal and bone toxicity

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU471

21 January 2018

Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents.

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU471

21 January 2018

Low bone mineral density, renal dysfunction, and fracture risk in HIV infection: a cross-sectional study

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU471

21 January 2018

Tenofovir treatment of primary osteoblasts alters gene expression profiles: implications for bone mineral density loss

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU471

21 January 2018

Bone mineral density in HIV-negative men participating in a tenofovir pre-exposure prophylaxis randomized clinical trial in San Francisco

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU471

21 January 2018

Reduced bone mineral density and altered bone turnover markers in patients with non-cirrhotic chronic hepatitis B or C infection

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU471

21 January 2018

Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU471

21 January 2018

Bone disorders in chronic liver disease

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU471

21 January 2018

Guidelines on the management of osteoporosis associated with chronic liver disease

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU471

21 January 2018

Bone mineral density changes among HIV-uninfected young adults in a randomised trial of pre-exposure prophylaxis with tenofovir-emtricitabine or placebo in Botswana

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU471

21 January 2018

Risk of hip fracture associated with untreated and treated chronic hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU471

21 January 2018

Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis.

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU471

21 January 2018

Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU471

21 January 2018

Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU471

21 January 2018

Hepatitis B virus resistance to antiviral drugs: where are we going?

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU471

21 January 2018

Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses.

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU471

21 January 2018

Bone mineral density, serum insulin-like growth factor I, and bone turnover markers in viral cirrhosis.

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU471

21 January 2018

Vitamin D and bone disease

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU471

21 January 2018

HLA alleles association with changes in bone mineral density in HIV-1-infected adults changing treatment to tenofovir-emtricitabine or abacavir-lamivudine

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU471

21 January 2018

Serum HBsAg Decline During Long-term Potent Nucleos(t)ide Analogue Therapy for Chronic Hepatitis B and Prediction of HBsAg Loss

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU471

21 January 2018

Identifiers

10.1093/INFDIS/JIU471

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42197985&oldid=1564221659"